Stock Financial Ratios, Dividends, Split History
FPI / Farmland Partners Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||200.50|
|Enterprise Value ($M)||720.82|
|Book Value ($M)||357.35|
|Book Value / Share||10.87|
|Price / Book||0.57|
|NCAV / Share||n/a|
|Price / NCAV||n/a|
|Weighted Average Number Of Diluted Shares Outstanding||31,210,000|
|Weighted Average Number Of Shares Outstanding Basic||31,210,000|
|Common Shares Outstanding||33,334,849|
|Pro Forma Weighted Average Shares Outstanding Diluted||32,340,000|
|Common Stock Shares Outstanding Fully Diluted||38,000,000|
|Common Stock Shares Outstanding||33,334,849|
|Weighted Average Basic Shares Outstanding Pro Forma||32,340,000|
|Temporary Equity Shares Outstanding||6,037,500|
|Altman Z Score||N/A|
|Beneish M Score||N/A|
|Management Effectiveness (mra)|
|Return on Invested Capital (ROIC)||0.01|
|Return on Assets (ROA)||0.01|
|Return on Equity (ROE)||0.04|
|Income Statement (mra) ($M)|
|Real Estate Revenue Net||46,219,000.00|
|Earnings Per Share Diluted||0.03|
|Earnings Per Share Basic||0.03|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||0.93|
|Cash from Investing||-234.11|
|Cash from Financing||-234.11|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1591670|
|SIC 6798 - Real Estate Investment Trusts|
Stock splits are used by Farmland Partners Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
While I admire the effort to track down the facts, the theory that FPI was inflating revenues did not smell right to me. This bear became a bull.
Stocks were looking for direction on Wednesday with a fairly light day on economic data. Investors have had less faith and have seen lower rewards from buying the dips than in prior years. Many of those same investors have also been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and also for the longer term, into 2019 and beyond. (25-1)
The MSCI US REIT Index has underperformed the S&P 500 for two weeks in a row despite remaining relatively flat. (2-0)
On the long side, there's a mix of screener ideas, what to do after the market sells the news, and one case of trying to get ahead of news. (17-0)
As most of you already know, Farmland Partners (FPI) dropped almost 40% on 7/11/18 related to a short article from someone with the pseudonym Rota Fortunae in which the author insinuated various financial shenanigans. Some of the issues raised had been the topic of discussion previously while others were newly introduced. This was not the first bearish article on FPI and it will likely not be the last.
as of ET